{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:08:15Z","timestamp":1782256095302,"version":"3.54.5"},"reference-count":154,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bone metastasis is a major cause of morbidity within solid tumours of the breast, prostate, lung and kidney. Metastasis to the skeleton is associated with a wide range of complications including bone fractures, spinal cord compression, hypercalcaemia and increased bone pain. Improved treatments for bone metastasis, such as the use of anti-bone resorptive bisphosphonate agents, within post-menopausal women have improved disease-free survival; however, these treatments are not without side effects. There is thus a need for biomarkers, which will predict the risk of developing the spread to bone within these cancers. The application of molecular profiling techniques, together with animal model systems and engineered cell-lines has enabled the identification of a series of potential bone-metastasis biomarker molecules predictive of bone metastasis risk. Some of these biomarker candidates have been validated within patient-derived samples providing a step towards clinical utility. Recent developments in multiplex biomarker quantification now enable the simultaneous measurement of up to 96 micro-RNA\/protein molecules in a spatially defined manner with single-cell resolution, thus enabling the characterisation of the key molecules active at the sites of pre-metastatic niche formation as well as tumour-stroma signalling. These technologies have considerable potential to inform biomarker discovery. Additionally, a potential future extension of these discoveries could also be the identification of novel drug targets within cancer spread to bone. This chapter summarises recent findings in biomarker discovery within the key bone metastatic cancers (breast, prostate, lung and renal cell carcinoma). Tissue-based and circulating blood-based biomarkers are discussed from the fields of genomics, epigenetic regulation (micro-RNAs) and protein\/cell-signalling together with a discussion of the potential future development of these markers towards clinical development.<\/jats:p>","DOI":"10.3390\/cancers12082109","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T03:36:38Z","timestamp":1596080198000},"page":"2109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases"],"prefix":"10.3390","volume":"12","author":[{"given":"Steven L.","family":"Wood","sequence":"first","affiliation":[{"name":"Department of Oncology and Metabolism, Medical School, Beech Hill Road, Sheffield S10 2RX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2165\/00002512-200118120-00002","article-title":"Strategies for management of prostate cancer-related bone pain","volume":"18","author":"Pelger","year":"2001","journal-title":"Drugs Aging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3816\/SCT.2006.n.012","article-title":"Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases","volume":"3","author":"Costa","year":"2006","journal-title":"Support. Cancer Ther."},{"key":"ref_4","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J. Support. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01243894-200607000-00012","article-title":"Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer","volume":"1","author":"Delea","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_10","unstructured":"(2020, June 27). Pros. Available online: https:\/\/www.healthline.com\/health\/prostate-cancer-prognosis-life-expectancy-bone-metastases."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_12","first-page":"25","article-title":"Prognostic factors for survival in patients with inoperable lung cancer","volume":"65","author":"Stanley","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/thx.33.2.228","article-title":"Bronchial carcinoma and long-term survival. Retrospective study of 433 patients who underwent resection","volume":"33","author":"Freise","year":"1978","journal-title":"Thorax"},{"key":"ref_14","unstructured":"(2020, June 29). SEER. Available online: http:\/\/seer.cancer\/gov\/statfacts\/index.html."},{"key":"ref_15","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6397S","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12253-009-9184-7","article-title":"Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases","volume":"16","author":"Szendroi","year":"2010","journal-title":"Pathol. Oncol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: A secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"djv256","DOI":"10.1093\/jnci\/djv256","article-title":"Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis","volume":"107","author":"Pavlovic","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1176935119866842","DOI":"10.1177\/1176935119866842","article-title":"Dedicator of Cytokinesis 4: A Potential Prognostic and Predictive Biomarker Within the Metastatic Spread of Breast Cancer to Bone","volume":"18","author":"Brown","year":"2019","journal-title":"Cancer Inform."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Westbrook, J.A., Cairns, D.A., Peng, J., Speirs, V., Hanby, A.M., Holen, I., Wood, S.L., Ottewell, P.D., Marshall, H., and Banks, R.E. (2016). CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv360"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/path.5197","article-title":"Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer","volume":"247","author":"Westbrook","year":"2019","journal-title":"J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/bonekey.2015.56","article-title":"Tumour-derived miRNAs and bone metastasis","volume":"4","author":"Croset","year":"2015","journal-title":"Bonekey Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/14789450.3.5.483","article-title":"Proteomic profiling of differentiating osteoblasts","volume":"3","author":"Blonder","year":"2006","journal-title":"Expert Rev. Proteom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1101\/gad.1854909","article-title":"Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases","volume":"23","author":"Guise","year":"2009","journal-title":"Genes Dev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semcdb.2008.07.016","article-title":"Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption","volume":"19","author":"Sims","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.suronc.2012.06.001","article-title":"Matrix metalloproteinases: Potential therapy to prevent the development of second malignancies after breast radiotherapy","volume":"21","author":"Lara","year":"2012","journal-title":"Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tauro, M., and Lynch, C.C. (2018). Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis. Cancers, 10.","DOI":"10.3390\/cancers10060185"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.phrs.2019.04.030","article-title":"Osteopontin as a multifaceted driver of bone metastasis and drug resistance","volume":"144","author":"Pang","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wong, S.K., Mohamad, N.V., Giaze, T.R., Chin, K.Y., Mohamed, N., and Ima-Nirwana, S. (2019). Prostate Cancer and Bone Metastases: The Underlying Mechanisms. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102587"},{"key":"ref_33","first-page":"119","article-title":"Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: Immunohistochemical study","volume":"34","author":"Spanjol","year":"2010","journal-title":"Coll. Antropol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100207","DOI":"10.1016\/j.bonr.2019.100207","article-title":"Bone morphogenetic proteins: Their role in regulating osteoclast differentiation","volume":"10","author":"Huntley","year":"2019","journal-title":"Bone Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","article-title":"Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04)","volume":"13","author":"Coleman","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cam4.1932","article-title":"A gene expression signature-based nomogram model in prediction of breast cancer bone metastases","volume":"8","author":"Zhao","year":"2019","journal-title":"Cancer Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/1878-0261.12526","article-title":"Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor","volume":"13","author":"Thysell","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0973-1482.200597","article-title":"Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euf.2017.09.016","article-title":"Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma","volume":"4","author":"Becerra","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_40","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A comprehensive review of denosumab for bone metastasis in patients with solid tumors","volume":"32","author":"Gul","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_43","first-page":"330","article-title":"Radium-223 in the treatment of bone metastasis in patients with castration-resistant prostate cancer. Review and procedure","volume":"37","year":"2018","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/cco.2018.06.05","article-title":"Advances in treatment of metastatic breast cancer with bone metastasis","volume":"7","author":"Wu","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ctrv.2016.09.013","article-title":"Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials","volume":"50","author":"LeVasseur","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: Molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-Targeted Therapies in Cancer-Induced Bone Disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_50","first-page":"181","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review","volume":"59","author":"Vescovi","year":"2010","journal-title":"Minerva Stomatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-012-1216-7","article-title":"Bisphosphonates: Effects on osteoblast","volume":"68","author":"Maruotti","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bonekey.2015.35","article-title":"Bone remodeling markers and bone metastases: From cancer research to clinical implications","volume":"4","author":"Ferreira","year":"2015","journal-title":"Bonekey Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_57","first-page":"89","article-title":"Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer","volume":"35","author":"Westerhuis","year":"1997","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"ref_58","first-page":"214","article-title":"Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer","volume":"22","author":"Kong","year":"2007","journal-title":"Int. J. Biol. Markers"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbo.2013.01.002","article-title":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials","volume":"2","author":"Coleman","year":"2013","journal-title":"J. Bone Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"dju013","DOI":"10.1093\/jnci\/dju013","article-title":"Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: Results from SWOG 0421","volume":"106","author":"Lara","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF02967492","article-title":"Evaluation of bone metabolic markers in breast cancer with bone metastasis","volume":"8","author":"Wada","year":"2001","journal-title":"Breast Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cca.2016.07.005","article-title":"Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy","volume":"460","author":"Lumachi","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3727\/096504016X14768398678750","article-title":"Validity of Osteoprotegerin and Receptor Activator of NF-kappaB Ligand for the Detection of Bone Metastasis in Breast Cancer","volume":"25","author":"Elfar","year":"2017","journal-title":"Oncol. Res."},{"key":"ref_67","first-page":"1961","article-title":"Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas","volume":"27","author":"Oremek","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: A longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/0973-1482.145842","article-title":"Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: A systematic review and meta-analysis","volume":"10","author":"Du","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic bone disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12967-016-0893-x","article-title":"Regulatory mechanisms of microRNA expression","volume":"14","author":"Gulyaeva","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"63038","DOI":"10.18632\/oncotarget.18593","article-title":"Circulating miRNA-24 and its target YKL-40 as potential biomarkers in patients with coronary heart disease and type 2 diabetes mellitus","volume":"8","author":"Deng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9628","DOI":"10.1158\/0008-5472.CAN-05-2352","article-title":"A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation","volume":"65","author":"Hayashita","year":"2005","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1073\/pnas.0508889103","article-title":"microRNAs exhibit high frequency genomic alterations in human cancer","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014Micrornas with a role in cancer","volume":"6","author":"Slack","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","first-page":"1","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct Target. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5306\/wjco.v5.i2.71","article-title":"Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis?","volume":"5","author":"Christodoulatos","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/cgp.20108","article-title":"The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs","volume":"16","author":"Weidle","year":"2019","journal-title":"Cancer Genom. Proteom."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature13375","article-title":"miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2","volume":"512","author":"Krzeszinski","year":"2014","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.22203\/eCM.v028a19","article-title":"Role and regulation of RUNX2 in osteogenesis","volume":"28","author":"Bruderer","year":"2014","journal-title":"Eur. Cell Mater."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1158\/0008-5472.CAN-17-3058","article-title":"miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes","volume":"78","author":"Croset","year":"2018","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-018-1059-y","article-title":"Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts","volume":"20","author":"Liu","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"79032","DOI":"10.18632\/oncotarget.12593","article-title":"Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells","volume":"7","author":"Taipaleenmaki","year":"2016","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10585-014-9682-1","article-title":"Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer","volume":"31","author":"Johnson","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0645-7","article-title":"Downregulation of miR-141-3p promotes bone metastasis via activating NF-kappaB signaling in prostate cancer","volume":"36","author":"Huang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-14-1784","article-title":"miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer","volume":"20","author":"Gururajan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1158\/1078-0432.CCR-14-0305","article-title":"miR-409-3p\/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer","volume":"20","author":"Josson","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1038\/onc.2014.212","article-title":"Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis","volume":"34","author":"Josson","year":"2015","journal-title":"Oncogene"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Hagan, J.P., O\u2019Neill, B.L., Stewart, C.L., Kozlov, S.V., and Croce, C.M. (2009). At least ten genes define the imprinted Dlk1-Dio3 cluster on mouse chromosome 12qF1. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004352"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/onc.2013.451","article-title":"MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells","volume":"33","author":"Formosa","year":"2014","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"19483","DOI":"10.1074\/jbc.M110.131995","article-title":"Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells","volume":"285","author":"Liu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000495473","article-title":"Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer","volume":"42","author":"Peng","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_95","first-page":"2376","article-title":"Serum microRNA-139-5p is downregulated in lung cancer patients with lytic bone metastasis","volume":"39","author":"Xu","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/1759-7714.13308","article-title":"Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5","volume":"11","author":"Ai","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.urolonc.2007.01.019","article-title":"Micro-RNA profiling in kidney and bladder cancers","volume":"25","author":"Gottardo","year":"2007","journal-title":"Urol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.2437","article-title":"Genome-wide microRNA expression profiling in renal cell carcinoma: Significant down-regulation of miR-141 and miR-200c","volume":"216","author":"Nakada","year":"2008","journal-title":"J. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3892\/ijo_00000318","article-title":"MicroRNA profiling of human kidney cancer subtypes","volume":"35","author":"Petillo","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1111\/j.1582-4934.2009.00705.x","article-title":"MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy","volume":"13","author":"Jung","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.urology.2009.10.033","article-title":"Identification of a microRNA panel for clear-cell kidney cancer","volume":"75","author":"Juan","year":"2010","journal-title":"Urology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.7150\/ijbs.5106","article-title":"Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas","volume":"8","author":"Wotschofsky","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/bioinformatics\/btp299","article-title":"DIANA-mirPath: Integrating human and mouse microRNAs in pathways","volume":"25","author":"Papadopoulos","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10549-015-3352-0","article-title":"Retrospective analysis of metastatic behaviour of breast cancer subtypes","volume":"150","author":"Halfwerk","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.7150\/thno.22523","article-title":"CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Hesse, E., Schroder, S., Brandt, D., Pamperin, J., Saito, H., and Taipaleenmaki, H. (2019). Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight, 5.","DOI":"10.1172\/jci.insight.125543"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2014.01.010","article-title":"Dickkopf-1 as a mediator and novel target in malignant bone disease","volume":"346","author":"Rachner","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr3616","article-title":"Dickkopf-1 is regulated by the mevalonate pathway in breast cancer","volume":"16","author":"Rachner","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10585-018-9937-3","article-title":"Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases","volume":"35","author":"Kasoha","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41388-018-0456-0","article-title":"A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERalpha-positive breast cancer cells","volume":"38","author":"Li","year":"2019","journal-title":"Oncogene"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jso.23737","article-title":"Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer","volume":"110","author":"Park","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Sutherland, A., Forsyth, A., Cong, Y., Grant, L., Juan, T.H., Lee, J.K., Klimowicz, A., Petrillo, S.K., Hu, J., and Chan, A. (2016). The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv338"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: A summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J. Urol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2013.07.001","article-title":"Predicting the risk of bone metastasis in prostate cancer","volume":"40","author":"Briganti","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","article-title":"The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications","volume":"24","author":"Thysell","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"Scher","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdn544","article-title":"Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience","volume":"20","author":"Olmos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Okegawa, T., Itaya, N., Hara, H., Tambo, M., and Nutahara, K. (2016). Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122008"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","article-title":"Detection of circulating tumor cells in different stages of prostate cancer","volume":"139","author":"Thalgott","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/pros.22639","article-title":"Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases","volume":"73","author":"Larson","year":"2013","journal-title":"Prostate"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2012.04.016","article-title":"Serum sclerostin levels in Paget\u2019s disease and prostate cancer with bone metastases with a wide range of bone turnover","volume":"51","author":"Yavropoulou","year":"2012","journal-title":"Bone"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1200\/JCO.2006.06.1952","article-title":"Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: A retrospective case-control study","volume":"24","author":"Papotti","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/cam4.1363","article-title":"Differentially expressed and survival-related proteins of lung adenocarcinoma with bone metastasis","volume":"7","author":"Yang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/cncr.10828","article-title":"Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia","volume":"95","author":"Hiraki","year":"2002","journal-title":"Cancer"},{"key":"ref_130","first-page":"3424","article-title":"SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic target","volume":"42","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"79469","DOI":"10.18632\/oncotarget.18446","article-title":"Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases","volume":"8","author":"Qiao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3892\/or.2011.1572","article-title":"A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro","volume":"27","author":"Wang","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10585-015-9731-4","article-title":"Eight proteins play critical roles in RCC with bone metastasis via mitochondrial dysfunction","volume":"32","author":"Wang","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.18632\/oncotarget.15222","article-title":"Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"45525","DOI":"10.18632\/oncotarget.9997","article-title":"C-met inhibition blocks bone metastasis development induced by renal cancer stem cells","volume":"7","author":"Belisario","year":"2016","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-020-00959-3","article-title":"Targeted remodeling of breast cancer and immune cell homing niches by exosomal integrins","volume":"15","author":"Myint","year":"2020","journal-title":"Diagn. Pathol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Wong, G.L., Jalboush, S.A., and Lo, H.W. (2020). Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis. Cancers, 12.","DOI":"10.3390\/cancers12071827"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Ponzetti, M., and Rucci, N. (2020). Switching Homes: How Cancer Moves to Bone. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114124"},{"key":"ref_140","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/aja.aja_1_18","article-title":"Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer","volume":"20","author":"Gourdin","year":"2018","journal-title":"Asian J. Androl."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","article-title":"Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system","volume":"13","author":"Riethdorf","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-012-2045-1","article-title":"Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study","volume":"134","author":"Pestrin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Agelaki, S., Kalykaki, A., Markomanolaki, H., Papadaki, M.A., Kallergi, G., Hatzidaki, D., Kalbakis, K., Mavroudis, D., and Georgoulias, V. (2015). Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123683"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Summers, M.A., McDonald, M.M., and Croucher, P.I. (2020). Cancer Cell Dormancy in Metastasis. Cold Spring Harb. Perspect. Med., 10.","DOI":"10.1101\/cshperspect.a037556"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/pros.23896","article-title":"Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer","volume":"79","author":"Cackowski","year":"2019","journal-title":"Prostate"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.gde.2009.12.002","article-title":"Circulating tumor cells: A window into cancer biology and metastasis","volume":"20","author":"Maheswaran","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_149","first-page":"332","article-title":"The emerging role of circulating tumor cells in cancer management","volume":"12","author":"Li","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e02826","DOI":"10.1016\/j.heliyon.2019.e02826","article-title":"Multi-biomarker panel signature as the key to diagnosis of ovarian cancer","volume":"5","author":"Muinao","year":"2019","journal-title":"Heliyon"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10585-012-9481-5","article-title":"Location matters: Osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo","volume":"29","author":"Brown","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and Significance of the Pre-metastatic Niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_153","unstructured":"(2020, June 29). DSP. Available online: https:\/\/www.nanostring.com\/scientific-content\/technology-overview\/digital-spatial-profiling-technology."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s40425-019-0753-3","article-title":"Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients","volume":"7","author":"Ihle","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:52:36Z","timestamp":1760176356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":154,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082109"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082109","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]}}}